Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX 22 Receivables Turnover is 2.22 as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 22/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 77.83% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Epigenomics AG's Revenue for the
six
months ended in Dec. 2025 was €0.02 Mil. Epigenomics AG's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.01 Mil.
Hence, Epigenomics AG's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.22.
Epigenomics AG (FRA:ECX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Epigenomics AG Receivables Turnover Related Terms
Epigenomics AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ECX vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a Receivables Turnover of 2.22 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Epigenomics AG and its competitors. According to the industry distribution chart, Epigenomics AG ranks #158 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 77.8%.
Is Epigenomics AG's Receivables Turnover too high?
Epigenomics AG's current Receivables Turnover is 2.22. The Medical Diagnostics & Research industry median Receivables Turnover is 5.37. Epigenomics AG's value of 2.22 is 58.7% below this industry median. Based on the distribution chart, Epigenomics AG ranks #158 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #158 out of 203 companies for Receivables Turnover. This places Epigenomics AG in the lower half of its industry. The industry median Receivables Turnover is 5.37. Epigenomics AG's value of 2.22 is 58.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.37, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigenomics AG's current Receivables Turnover of 2.22 is 58.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current Receivables Turnover is 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.87 — trading 866.7% above its estimated fair value. The current Receivables Turnover is 2.22 and 58.7% below the Medical Diagnostics & Research industry median of 5.37. Epigenomics AG's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Receivables Turnover is 2.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.87 is trading 866.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
Receivables Turnover: 2.22
GF Value™: €0.09 vs. price of €0.87 (866.7% above fair value)
Industry Position: 58.7% below the Medical Diagnostics & Research median (#158 of 203)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
22GF Score
Get the complete analysis for FRA:ECX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
